Walter Sofronoff KC has argued that a report into his inquiry into the prosecution of Bruce Lehrmann is not subject to parliamentary privilege merely because it was tabled in the Legislative Assembly, arguing such a finding would preclude judicial review.
The prospective developer of the Hyde Park Inn site in Sydney is appealing a decision which rejected its bid to delay a $95 million payment to the NSW Returned Service League to settle the sale.
US-based investment firm Carlyle has announced the launch of a clean energy infrastructure platform for the development of solar, battery storage and green hydrogen projects in Australia and the UK.
EnergyAustralia has admitted that its ‘Go Neutral’ carbon offset product did not prevent or reverse the harms associated with the burning of fossil fuels.
A judge hearing Maurice Blackburn’s application for a 30 per cent group costs order in a consumer class action against JB Hi-Fi has opined that an all-in group costs order was a better deal for group matters than the return in a typical funded case.
AkzoNobel has had some success in its late bid to have Japanese oil company INPEX produce documents filed in related proceedings against its insurers in their dispute over allegedly defective coating used on the $45 billion Ichthys natural gas project.
The New South Wales Supreme Court of Appeal has clarified that payment claims and adjudication notices sent via email can constitute service and trigger relevant limitation periods under the Security of Payment Act.
Former Victorian Liberal party leader John Pesutto has been ordered to pay $2.3 million in costs in MP Moira Deeming’s defamation suit over statements found to have conveyed that she had links to neo-Nazis.
EnergyAustralia has reached a settlement with advocacy group Parents for Climate in a suit accusing it of falsely promoting its carbon offset products as carbon neutral.
Sandoz has accused Amgen of ‘dragging the chain’ as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.